[{"address1": "9920 Pacific Heights Boulevard", "address2": "Suite 350", "city": "San Diego", "state": "CA", "zip": "92121", "country": "United States", "phone": "858 704 4660", "website": "https://www.vikingtherapeutics.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TR\u00df), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; VK2735, a novel dual agonist of the glucagon-like peptide, which is in Phase 1 SAD/MAD clinical trial, and VK0214, an orally available tissue and receptor-subtype selective agonist of the TR\u00df for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.", "fullTimeEmployees": 50, "companyOfficers": [{"maxAge": 1, "name": "Dr. Brian  Lian Ph.D.", "age": 58, "title": "President, CEO & Director", "yearBorn": 1966, "fiscalYear": 2024, "totalPay": 1193748, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Gregory S. Zante CPA, CPA", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1971, "fiscalYear": 2024, "totalPay": 713000, "exercisedValue": 20395892, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Marianne  Mancini", "age": 59, "title": "Chief Operating Officer", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 735000, "exercisedValue": 8888907, "unexercisedValue": 636903}, {"maxAge": 1, "name": "Mr. Michael  Morneau", "age": 59, "title": "Vice President of Finance & Administration", "yearBorn": 1965, "fiscalYear": 2024, "totalPay": 375333, "exercisedValue": 0, "unexercisedValue": 490518}, {"maxAge": 1, "name": "Dr. Geoffrey E. Barker Ph.D.", "title": "Chief Development Officer", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 7, "boardRisk": 9, "compensationRisk": 9, "shareHolderRightsRisk": 8, "overallRisk": 9, "governanceEpochDate": 1759276800, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 33.92, "open": 35.0, "dayLow": 33.0, "dayHigh": 35.25, "regularMarketPreviousClose": 33.92, "regularMarketOpen": 35.0, "regularMarketDayLow": 33.0, "regularMarketDayHigh": 35.25, "payoutRatio": 0.0, "beta": 0.635, "forwardPE": -22.7947, "volume": 4380794, "regularMarketVolume": 4380794, "averageVolume": 6464370, "averageVolume10days": 4397010, "averageDailyVolume10Day": 4397010, "bid": 34.26, "ask": 34.69, "bidSize": 26, "askSize": 26, "marketCap": 3890710784, "fiftyTwoWeekLow": 18.92, "fiftyTwoWeekHigh": 81.73, "allTimeHigh": 99.41, "allTimeLow": 0.88, "fiftyDayAverage": 28.8281, "twoHundredDayAverage": 29.280375, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": 3176896000, "profitMargins": 0.0, "floatShares": 110558587, "sharesOutstanding": 113036344, "sharesShort": 25450539, "sharesShortPriorMonth": 27010893, "sharesShortPreviousMonthDate": 1757894400, "dateShortInterest": 1760486400, "sharesPercentSharesOut": 0.2252, "heldPercentInsiders": 0.021340001, "heldPercentInstitutions": 0.67724997, "shortRatio": 4.7, "shortPercentOfFloat": 0.2698, "impliedSharesOutstanding": 112445000, "bookValue": 6.341, "priceToBook": 5.4281654, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1759190400, "netIncomeToCommon": -237394000, "trailingEps": -2.12, "forwardEps": -1.51, "52WeekChange": -0.5381106, "SandP52WeekChange": 0.16625166, "quoteType": "EQUITY", "currentPrice": 34.42, "targetHighPrice": 125.0, "targetLowPrice": 36.0, "targetMeanPrice": 92.47059, "targetMedianPrice": 100.0, "recommendationMean": 1.47059, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 17, "totalCash": 714569984, "totalCashPerShare": 6.322, "totalDebt": 755000, "quickRatio": 27.413, "currentRatio": 28.339, "debtToEquity": 0.106, "returnOnAssets": -0.20482, "returnOnEquity": -0.29227, "freeCashflow": -150900256, "operatingCashflow": -224576000, "grossMargins": 0.0, "ebitdaMargins": 0.0, "operatingMargins": 0.0, "financialCurrency": "USD", "symbol": "VKTX", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1761350213, "regularMarketTime": 1761336000, "shortName": "Viking Therapeutics, Inc.", "longName": "Viking Therapeutics, Inc.", "marketState": "CLOSED", "regularMarketChangePercent": 1.47406, "regularMarketPrice": 34.42, "exchange": "NCM", "messageBoardId": "finmb_246791410", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "priceEpsCurrentYear": -13.202154, "fiftyDayAverageChange": 5.591898, "fiftyDayAverageChangePercent": 0.19397387, "twoHundredDayAverageChange": 5.1396236, "twoHundredDayAverageChangePercent": 0.17553134, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1430227800000, "postMarketChangePercent": 0.348642, "postMarketPrice": 34.54, "postMarketChange": 0.120003, "regularMarketChange": 0.5, "regularMarketDayRange": "33.0 - 35.25", "fullExchangeName": "NasdaqCM", "averageDailyVolume3Month": 6464370, "fiftyTwoWeekLowChange": 15.499998, "fiftyTwoWeekLowChangePercent": 0.8192388, "fiftyTwoWeekRange": "18.92 - 81.73", "fiftyTwoWeekHighChange": -47.310005, "fiftyTwoWeekHighChangePercent": -0.57885724, "fiftyTwoWeekChangePercent": -53.81106, "earningsTimestamp": 1761163200, "earningsTimestampStart": 1761163200, "earningsTimestampEnd": 1761163200, "earningsCallTimestampStart": 1761165000, "earningsCallTimestampEnd": 1761165000, "isEarningsDateEstimate": false, "epsTrailingTwelveMonths": -2.12, "epsForward": -1.51, "epsCurrentYear": -2.60715, "displayName": "Viking Therapeutics", "trailingPegRatio": null, "__fetch_time": "2025-10-25"}]